Skip to content
Catalyst

acetylsalicylic acidWhat was measured

Measured, with no finding

323 endpoints

Show what was measuredHide what was measured
  • abdominal pain

    unclear

    Risks of abdominal pain and GERD-related symptoms were non-significantly increased in the ASA groups

    PMID 21902288 · one of two readings recorded this

  • adverse events by daily dose

    increases

    More patients receiving doses >1000 mg/day reported AEs (18.1%) than those receiving doses <500 mg/day (15.1%) or those receiving placebo (13.5%)

    PMID 21902288 · one of two readings recorded this

  • adverse events, interaction with age or sex

    no effect

    There was no interaction by age or sex for any of the events of interest

    PMID 21902288 · one of two readings recorded this

  • adverse events, multiple-dose versus single-dose

    increases

    Multiple-dose administration of ASA (up to 5 days) was associated with an increased incidence of AEs (16.2%) when compared with single-dose administration (12.8%)

    PMID 21902288 · one of two readings recorded this

  • adverse events, multiple-dose versus single-dose

    increases

    this was similar to results observed in the placebo arm (17.0% and 12.8%, respectively)

    PMID 21902288 · one of two readings recorded this

  • cerebral hemorrhage and hypersensitivity reaction

    no effect

    No cerebral hemorrhage or hypersensitivity reaction occurred in any of the trials

    PMID 21902288 · one of two readings recorded this

  • combined dyspepsia terms

    no effect

    No statistically significant differences for the combined terms of dyspepsia were found between treatments, although the ORs were >1.0 for the comparisons with ibuprofen

    PMID 21902288 · one of two readings recorded this

  • GERD-related symptoms

    unclear

    Risks of abdominal pain and GERD-related symptoms were non-significantly increased in the ASA groups

    PMID 21902288 · one of two readings recorded this

  • headache

    decreases

    There was a reduction in the risk of headache from ASA and there were non-significant increases in tinnitus and non-GI bleeding

    PMID 21902288 · one of two readings recorded this

  • minor dyspepsia, age interaction

    increases, p = 0.052

    a borderline statistically significant (p = 0.052) interaction effect was observed for patients ≥40 years of age when compared with those <40 years of age (OR 1.98 [95% CI 1.2, 3.1])

    PMID 21902288 · one of two readings recorded this

  • non-GI bleeding

    unclear

    There was a reduction in the risk of headache from ASA and there were non-significant increases in tinnitus and non-GI bleeding

    PMID 21902288 · one of two readings recorded this

  • overall incidence of adverse events, risk difference

    no effect

    risk difference 1.0% (95 % CI −0.5, 2.5)

    PMID 21902288 · one of two readings recorded this

  • overall incidence of adverse events

    no effect

    similar between subjects treated with ASA (741/4884; 15.2%) and those treated with placebo (580/3731; 15.5%).[OR 1.1; 95% CI 0.96, 1.2]

    PMID 21902288 · one of two readings recorded this

  • patient-reported gastrointestinal adverse events and overall adverse events, MedDRA-coded, ASA versus placebo (ASA arm includes combinations with vitamin C, caffeine, calcium, pseudoephedrine, lidocaine, dextromethorphan)

    no effect, 741/4884 (15.2%) with ASA versus 580/3731 (15.5%) with placebo for all AEs

    Not recorded as a finding: this platform holds no node for the endpoint

    The overall incidence of AEs was low, and was similar between subjects treated with ASA (741/4884; 15.2%) and those treated with placebo (580/3731; 15.5%).

    PMID 21902288 · one of two readings recorded this

  • patient-reported gastrointestinal adverse events (MedDRA-coded, incl. dyspepsia) after short-term mostly single-dose ASA versus placebo, pooled Cochran-Mantel-Haenszel odds ratio

    increases

    Not recorded as a finding: this platform holds no node for the endpoint

    GI AEs of any severity were more frequent in the ASA groups than in the placebo groups, as summarized in.

    PMID 21902288 · one of two readings recorded this

  • proportion of ASA-treated patients receiving a single dose

    n = 6181

    Of the 6181 patients allocated to ASA and ASA combinations, 5099 (82.5%) received a single dose, 1082 (17.5%) received a multiple-dose regimen, and 188 (3.0%) were treated for more than 5 days

    PMID 21902288 · one of two readings recorded this

  • serious GI adverse events and GI hemorrhage

    no effect

    There were very few serious GI adverse events

    PMID 21902288 · one of two readings recorded this

  • severe dyspepsia

    unclear

    severe dyspepsia was non-significantly less common in ASA subjects

    PMID 21902288 · one of two readings recorded this

  • tinnitus

    unclear

    There was a reduction in the risk of headache from ASA and there were non-significant increases in tinnitus and non-GI bleeding

    PMID 21902288 · one of two readings recorded this

  • extra UGIB cases associated with LDA use in RCTs

    increases

    The mean number of extra UGIB cases associated with LDA use in the RCTs was 1.2 per 1000 patients per year (95% CI 0.7 to 1.8)

    PMID 23516680 · one of two readings recorded this

  • number needed to harm for UGIB, observational studies

    increases

    819 (95% CI 617 to 1119) for observational studies

    PMID 23516680 · one of two readings recorded this

  • number needed to harm for UGIB, RCTs

    increases

    The number needed to harm was 816 (95% CI 560 to 1500) for RCTs

    PMID 23516680 · one of two readings recorded this

  • upper gastrointestinal bleeding (UGIB) risk, observational studies

    increases

    UGIB risk was most pronounced in observational studies (OR 3.1 [95% CI 2.5 to 3.7])

    PMID 23516680 · one of two readings recorded this

  • upper gastrointestinal bleeding (UGIB) risk, pooled odds ratio of RCTs of low-dose acetylsalicylic acid versus placebo

    increases, OR 1.5 [95% CI 1.2 to 1.8]

    Not recorded as a finding: this platform holds no node for the endpoint

    Meta-analysis of RCT data showed that LDA use was associated with a 50% increase in UGIB risk (OR 1.5 [95% CI 1.2 to 1.8]).

    PMID 23516680 · one of two readings recorded this

  • upper gastrointestinal bleeding (UGIB) risk, RCTs

    increases

    Meta-analysis of RCT data showed that LDA use was associated with a 50% increase in UGIB risk (OR 1.5 [95% CI 1.2 to 1.8])

    PMID 23516680 · one of two readings recorded this

  • upper gastrointestinal bleeding (UGIB) risk with low-dose aspirin, pooled odds ratio from randomised trials and from observational studies

    increases, OR 1.5 (95% CI 1.2 to 1.8) pooled across RCTs

    Not recorded as a finding: this platform holds no node for the endpoint

    Meta-analysis of RCT data showed that LDA use was associated with a 50% increase in UGIB risk (OR 1.5 [95% CI 1.2 to 1.8]).

    PMID 23516680 · one of two readings recorded this

  • fecal blood loss

    decreases

    patients receiving cimetidine experienced significantly less blood loss than those receiving placebo (mean ± standard deviation 4.1 ± 0.3 mL/day v. 2.2 ± 0.3 mL/day)

    PMID 23687524 · one of two readings recorded this

  • gastric ulcers

    decreases, p = 0.002

    Another study reported gastric ulcers, which occurred less frequently in the group receiving famotidine than in the placebo group (p = 0.002)

    PMID 23687524 · one of two readings recorded this

  • gastrointestinal hemorrhage confirmed by endoscopy

    decreases, n = 447

    patients who received an H2 blocker were significantly less likely to experience gastrointestinal hemorrhage than those who received placebo (n = 2 RCTs, 447 patients, OR 0.07, 95% CI 0.02–0.23; Figure 2)

    PMID 23687524 · one of two readings recorded this

  • gastrointestinal hemorrhage requiring admission to hospital

    no effect, p = 0.14

    gastrointestinal hemorrhage requiring admission to hospital (relative risk 0.11, 95% CI 0.01–2.01, p = 0.14)

    PMID 23687524 · one of two readings recorded this

  • gastrointestinal hemorrhage requiring blood transfusion

    no effect, p = 0.29

    gastrointestinal hemorrhage requiring blood transfusion (relative risk 0.20, 95% CI 0.01–4.06, p = 0.29)

    PMID 23687524 · one of two readings recorded this

  • harms reported (not related to H2 blockers)

    decreases

    In another RCT, fewer harms occurred in the famotidine group than in the placebo group (9 v. 15)

    PMID 23687524 · one of two readings recorded this

  • peptic ulcers

    decreases, n = 465

    H2 blockers were effective in reducing the incidence of peptic ulcers (n = 3 RCTs, 465 patients, OR 0.21, 95% CI 0.12–0.36)

    PMID 23687524 · one of two readings recorded this

  • peptic ulcers

    decreases

    The results were unchanged when the meta-analysis was conducted with only the 2 studies that excluded ulcers (OR 0.19, 95% CI 0.11–0.33, I2 = 0%)

    PMID 23687524 · one of two readings recorded this

  • ulcers observed by endoscopy

    no effect, p = 0.06

    One RCT reported no statistically significant changes observed by endoscopy between the placebo and cimetidine groups (p = 0.06)

    PMID 23687524 · one of two readings recorded this

  • amount of administered drugs

    no effect, p = 0.05

    the studied groups did not differ significantly in the amount of administered drugs (p > 0.05, the Pearson chi-squared test)

    PMID 32959110 · one of two readings recorded this

  • Aspirin reaction units, Visit 1

    decreases, p = 0.001

    Aspirin reaction units visit 1 (mean ± SD) | 489.0 ± 73.0a | 488.2 ± 83.0a | 638.3 ± 15.9b | = 0.001

    PMID 32959110 · one of two readings recorded this

  • Aspirin reaction units, Visit 2

    decreases, p = 0.001

    Aspirin reaction units visit 2 (mean ± SD) | 487.62 ± 77.4a | 460.10 ± 82.3a † | 639.2 ± 16.3b | = 0.001

    PMID 32959110 · one of two readings recorded this

  • BMI, non-dippers vs dippers

    unclear, p = 0.04

    with a mean ± SD of 31.4 ± 4.4 and 28.6 ± 44.1 (Mann-Whitney U test, p = 0.04)

    PMID 32959110 · one of two readings recorded this

  • BMI, weight, waist and hips

    no effect, p = 0.05

    did not differ significantly between the studied groups and did not change considerably between Visits 1 and 2 (p > 0.05, the Wilcoxon signed-rank test)

    PMID 32959110 · one of two readings recorded this

  • clinic DBP, change Visit 1 to Visit 2 (Wilcoxon)

    decreases, p = 0.0001, n = 56

    p (Wilcoxon) | p = 0.004 | p = 0.0001 | p > 0.05

    PMID 32959110 · one of two readings recorded this

  • clinic DBP, change Visit 1 to Visit 2 (Wilcoxon)

    decreases, p = 0.004, n = 58

    p (Wilcoxon) | p = 0.004 | p = 0.0001 | p > 0.05

    PMID 32959110 · one of two readings recorded this

  • clinic DBP, change Visit 1 to Visit 2 (Wilcoxon)

    no effect, p = 0.05, n = 61

    p (Wilcoxon) | p = 0.004 | p = 0.0001 | p > 0.05

    PMID 32959110 · one of two readings recorded this

  • clinic DBP change

    decreases, n = 56

    Although the group receiving ASA in the morning revealed a decrease in the clinic BP (by 2.5/1.7 mmHg), the statistically higher drop was displayed by patients using ASA in the evening (by 5.4/3.8 mmHg)

    PMID 32959110 · one of two readings recorded this

  • clinic DBP change

    decreases, n = 58

    Although the group receiving ASA in the morning revealed a decrease in the clinic BP (by 2.5/1.7 mmHg), the statistically higher drop was displayed by patients using ASA in the evening (by 5.4/3.8 mmHg)

    PMID 32959110 · one of two readings recorded this

  • clinic DBP

    no effect, p = 0.05

    Clinic DBP [mm Hg] | Visit 1 | > 0.05 | 88.8 ± 4.0 | 88.8 ± 5.3 | 89.0 ± 5.5

    PMID 32959110 · one of two readings recorded this

  • clinic DBP

    decreases, p = 0.05

    Visit 2 | < 0.05 | 87.2 ± 4.7 a | 85.0 ± 5.7 b | 87.9 ± 3.0 a

    PMID 32959110 · one of two readings recorded this

  • clinic SBP, change Visit 1 to Visit 2 (Wilcoxon)

    decreases, p = 0.0001, n = 56

    p (Wilcoxon) | p = 0.0001 | p = 0.0001 | p > 0.05

    PMID 32959110 · one of two readings recorded this

  • clinic SBP, change Visit 1 to Visit 2 (Wilcoxon)

    decreases, p = 0.0001, n = 58

    p (Wilcoxon) | p = 0.0001 | p = 0.0001 | p > 0.05

    PMID 32959110 · one of two readings recorded this

  • clinic SBP, change Visit 1 to Visit 2 (Wilcoxon)

    no effect, p = 0.05, n = 61

    p (Wilcoxon) | p = 0.0001 | p = 0.0001 | p > 0.05

    PMID 32959110 · one of two readings recorded this

  • clinic SBP change

    decreases, n = 56

    Although the group receiving ASA in the morning revealed a decrease in the clinic BP (by 2.5/1.7 mmHg), the statistically higher drop was displayed by patients using ASA in the evening (by 5.4/3.8 mmHg)

    PMID 32959110 · one of two readings recorded this

  • clinic SBP change

    decreases, n = 58

    Although the group receiving ASA in the morning revealed a decrease in the clinic BP (by 2.5/1.7 mmHg), the statistically higher drop was displayed by patients using ASA in the evening (by 5.4/3.8 mmHg)

    PMID 32959110 · one of two readings recorded this

  • clinic SBP

    no effect, p = 0.05

    Clinic SBP [mm Hg] | Visit 1 | > 0.05 | 145.5 ± 5.0 | 145.2 ± 6.7 | 145.1 ± 5.2

    PMID 32959110 · one of two readings recorded this

  • clinic SBP

    decreases, p = 0.05

    Visit 2 | < 0.05 | 143.0 ± 4.1 a | 139.8 ± 5.6 b | 144.2 ± 4.6 a

    PMID 32959110 · one of two readings recorded this

  • DBP 24-h, change Visit 1 to Visit 2 (Wilcoxon)

    decreases, p = 0.0001, n = 56

    p (Wilcoxon) | p > 0.05 | p = 0.0001 | p > 0.05

    PMID 32959110 · one of two readings recorded this

  • DBP 24-h

    no effect, p = 0.05

    DBP 24 [mm Hg] | Visit 1 | > 0.05 | 82.6 ± 4.4 | 82.3 ± 4.8 | 83.2 ± 5.1

    PMID 32959110 · one of two readings recorded this

  • DBP 24-h

    decreases, p = 0.05

    Visit 2 | < 0.05 | 82.3 ± 4.1 a | 78.7 ± 5.9 b | 83.1 ± 5.5 a

    PMID 32959110 · one of two readings recorded this

  • DBP daytime, change Visit 1 to Visit 2 (Wilcoxon)

    decreases, p = 0.0001, n = 56

    p (Wilcoxon) | p = 0.0048 | p = 0.0001 | p < 0.0001

    PMID 32959110 · one of two readings recorded this

  • DBP daytime, change Visit 1 to Visit 2 (Wilcoxon)

    decreases, p = 0.0048, n = 58

    p (Wilcoxon) | p = 0.0048 | p = 0.0001 | p < 0.0001

    PMID 32959110 · one of two readings recorded this

  • DBP daytime, change Visit 1 to Visit 2 (Wilcoxon)

    decreases, p = 0.0001, n = 61

    p (Wilcoxon) | p = 0.0048 | p = 0.0001 | p < 0.0001

    PMID 32959110 · one of two readings recorded this

  • DBP daytime

    no effect, p = 0.05

    DBP d [mm Hg] | Visit 1 | > 0.05 | 86.5 ± 5.2 | 86.4 ± 5.4 | 86.8 ± 5.1

    PMID 32959110 · one of two readings recorded this

  • DBP daytime

    no effect, p = 0.05

    Visit 2 | > 0.05 | 84.9 ± 5.2 | 84.3 ± 6.2 | 85.7 ± 5.5

    PMID 32959110 · one of two readings recorded this

  • DBP night, change Visit 1 to Visit 2 (Wilcoxon)

    decreases, p = 0.0001, n = 56

    p (Wilcoxon) | p > 0.05 | p = 0.0001 | p > 0.05

    PMID 32959110 · one of two readings recorded this

  • DBP night

    no effect, p = 0.05

    DBPn [mm Hg] | Visit 1 | > 0.05 | 79.5 ± 5.3 | 79.1 ± 4.7 | 79.1 ± 4.9

    PMID 32959110 · one of two readings recorded this

  • DBP night

    decreases, p = 0.05

    Visit 2 | < 0.05 | 78.4 ± 4.6 a | 74.5 ± 5.3 b | 78.4 ± 5.2 a

    PMID 32959110 · one of two readings recorded this

  • DBP24 change

    decreases, n = 56

    and in the 24-h BP measurements (SBP24 by 5.5 mmHg, DBP24 by 3.56 mmHg and MAP24 by 4.2 mmHg)

    PMID 32959110 · one of two readings recorded this

  • DBPn change

    decreases, n = 56

    only a group receiving ASA in the evening for 3 months revealed a significant decrease in the blood pressure at night (SBPn by 5.5 mmHg, DBPn by 4.6 mmHg and MAPn by 4.9 mmHg)

    PMID 32959110 · one of two readings recorded this

  • MAP 24-h, change Visit 1 to Visit 2 (Wilcoxon)

    decreases, p = 0.0001, n = 56

    p (Wilcoxon) | p > 0.05 | p = 0.0001 | p > 0.05

    PMID 32959110 · one of two readings recorded this

  • MAP 24-h

    no effect, p = 0.05

    [mm Hg] | Visit 1 | > 0.05 | 100.0 ± 3.9 | 99.7 ± 4.4 | 100.3 ± 4.6

    PMID 32959110 · one of two readings recorded this

  • MAP 24-h

    decreases, p = 0.05

    Visit 2 | < 0.05 | 99.2 ± 3.6 a | 95.5 ± 5.1 b | 100.2 ± 4.3 a

    PMID 32959110 · one of two readings recorded this

  • MAP daytime, change Visit 1 to Visit 2 (Wilcoxon)

    decreases, p = 0.0001

    p (Wilcoxon) | p = 0.0001 | p = 0.0001 | p = 0.0001

    PMID 32959110 · one of two readings recorded this

  • MAP daytime

    no effect, p = 0.05

    MAP d [mm Hg] | Visit 1 | > 0.05 | 104.1 ± 4.5 | 104.1 ± 4.9 | 104.3 ± 4.2

    PMID 32959110 · one of two readings recorded this

  • MAP daytime

    no effect, p = 0.05

    Visit 2 | > 0.05 | 102.6 ± 4.0 | 101.7 ± 5.2 | 102.4 ± 4.5

    PMID 32959110 · one of two readings recorded this

  • MAP night, change Visit 1 to Visit 2 (Wilcoxon)

    decreases, p = 0.0001, n = 56

    p (Wilcoxon) | p > 0.05 | p = 0.0001 | p > 0.05

    PMID 32959110 · one of two readings recorded this

  • MAP night

    no effect, p = 0.05

    MAPn [mm Hg] | Visit 1 | > 0.05 | 94.6 ± 4.2 | 94.6 ± 4.0 | 94.5 ± 4.1

    PMID 32959110 · one of two readings recorded this

  • MAP night

    decreases, p = 0.05

    Visit 2 | < 0.05 | 94.0 ± 3.8 a | 89.7 ± 4.6 b | 94.2 ± 4.0 a

    PMID 32959110 · one of two readings recorded this

  • MAP24 change

    decreases, n = 56

    and in the 24-h BP measurements (SBP24 by 5.5 mmHg, DBP24 by 3.56 mmHg and MAP24 by 4.2 mmHg)

    PMID 32959110 · one of two readings recorded this

  • MAPn change

    decreases, n = 56

    only a group receiving ASA in the evening for 3 months revealed a significant decrease in the blood pressure at night (SBPn by 5.5 mmHg, DBPn by 4.6 mmHg and MAPn by 4.9 mmHg)

    PMID 32959110 · one of two readings recorded this

  • NBPF increase between Visit 1 and Visit 2

    increases, n = 56

    only the group receiving ASA in the evening experienced a significant increase in the NBPF between Visit 1 and Visit 2 (by mean of 3.5%)

    PMID 32959110 · one of two readings recorded this

  • nocturnal blood pressure fall (NBPF), change Visit 1 to Visit 2 (Wilcoxon)

    increases, p = 0.0001, n = 56

    p (Wilcoxon) | p = 0.032 | p = 0.0001 | p = 0.0002

    PMID 32959110 · one of two readings recorded this

  • nocturnal blood pressure fall (NBPF), change Visit 1 to Visit 2 (Wilcoxon)

    decreases, p = 0.032, n = 58

    p (Wilcoxon) | p = 0.032 | p = 0.0001 | p = 0.0002

    PMID 32959110 · one of two readings recorded this

  • nocturnal blood pressure fall (NBPF), change Visit 1 to Visit 2 (Wilcoxon)

    decreases, p = 0.0002, n = 61

    p (Wilcoxon) | p = 0.032 | p = 0.0001 | p = 0.0002

    PMID 32959110 · one of two readings recorded this

  • nocturnal blood pressure fall (NBPF)

    no effect, p = 0.05

    NBPF [%] | Visit 1 | > 0.05 | 9.0 ± 3.0 | 9.1 ± 2.5 | 9.3 ± 2.8

    PMID 32959110 · one of two readings recorded this

  • nocturnal blood pressure fall (NBPF)

    increases, p = 0.05

    Visit 2 | < 0.05 | 8.3 ± 2.8 a | 11.8 ± 2.7 b | 7.9 ± 3.6 a

    PMID 32959110 · one of two readings recorded this

  • number of dippers

    increases, n = 56

    significantly increase the number of dippers in this group—nearly threefold, from 14 patients at Visit 1 to 39 patients at Visit 2

    PMID 32959110 · one of two readings recorded this

  • number of dippers

    decreases, n = 58

    In the case of the group with morning ASA administration, a decrease in patients identified as dippers was observed—from 22 at Visit 1 to only 16 at Visit 2

    PMID 32959110 · one of two readings recorded this

  • SBP 24-h, change Visit 1 to Visit 2 (Wilcoxon)

    decreases, p = 0.0001, n = 56

    p (Wilcoxon) | p > 0.05 | p = 0.0001 | p > 0.05

    PMID 32959110 · one of two readings recorded this

  • SBP 24-h

    no effect, p = 0.05

    SBP 24 [mm Hg] | Visit 1 | > 0.05 | 134.6 ± 6.2 | 134.4 ± 6.8 | 134.6 ± 6.3

    PMID 32959110 · one of two readings recorded this

  • SBP 24-h

    decreases, p = 0.05

    Visit 2 | < 0.05 | 132.8 ± 5.7 a | 128.9 ± 5.8 b | 134.2 ± 4.9 a

    PMID 32959110 · one of two readings recorded this

  • SBP daytime, change Visit 1 to Visit 2 (Wilcoxon)

    decreases, p = 0.0001, n = 56

    p (Wilcoxon) | p = 0.0014 | p = 0.0001 | p = 0.0001

    PMID 32959110 · one of two readings recorded this

  • SBP daytime, change Visit 1 to Visit 2 (Wilcoxon)

    decreases, p = 0.0014, n = 58

    p (Wilcoxon) | p = 0.0014 | p = 0.0001 | p = 0.0001

    PMID 32959110 · one of two readings recorded this

  • SBP daytime, change Visit 1 to Visit 2 (Wilcoxon)

    decreases, p = 0.0001, n = 61

    p (Wilcoxon) | p = 0.0014 | p = 0.0001 | p = 0.0001

    PMID 32959110 · one of two readings recorded this

  • SBP daytime

    no effect, p = 0.05

    SBP d [mm Hg] | Visit 1 | > 0.05 | 139.1 ± 6.5 | 139.4 ± 7.2 | 139.2 ± 6.1

    PMID 32959110 · one of two readings recorded this

  • SBP daytime

    no effect, p = 0.05

    Visit 2 | > 0.05 | 137.9 ± 5.5 | 136.5 ± 6.7 | 137.8 ± 5.2

    PMID 32959110 · one of two readings recorded this

  • SBP night, change Visit 1 to Visit 2 (Wilcoxon)

    decreases, p = 0.0001, n = 56

    p (Wilcoxon) | p > 0.05 | p = 0.0001 | p < 0.05

    PMID 32959110 · one of two readings recorded this

  • SBP night, change Visit 1 to Visit 2 (Wilcoxon)

    no effect, p = 0.05, n = 58

    p (Wilcoxon) | p > 0.05 | p = 0.0001 | p < 0.05

    PMID 32959110 · one of two readings recorded this

  • SBP night, change Visit 1 to Visit 2 (Wilcoxon)

    unclear, p = 0.05, n = 61

    p (Wilcoxon) | p > 0.05 | p = 0.0001 | p < 0.05

    PMID 32959110 · one of two readings recorded this

  • SBP night

    no effect, p = 0.05

    SBPn [mm Hg] | Visit 1 | > 0.05 | 125.7 ± 7.3 | 125.6 ± 7.0 | 125.2 ± 6.8

    PMID 32959110 · one of two readings recorded this

  • SBP night

    decreases, p = 0.05

    Visit 2 | < 0.05 | 125.2 ± 7.0 a | 120.1 ± 6.9 b | 125.7 ± 6.6 a

    PMID 32959110 · one of two readings recorded this

  • SBP24 change

    decreases, n = 56

    and in the 24-h BP measurements (SBP24 by 5.5 mmHg, DBP24 by 3.56 mmHg and MAP24 by 4.2 mmHg)

    PMID 32959110 · one of two readings recorded this

  • SBPn change

    decreases, n = 56

    only a group receiving ASA in the evening for 3 months revealed a significant decrease in the blood pressure at night (SBPn by 5.5 mmHg, DBPn by 4.6 mmHg and MAPn by 4.9 mmHg)

    PMID 32959110 · one of two readings recorded this

  • uric acid concentration

    increases, n = 56

    uric acid, which concentration at Visit 2 was increased in the group receiving ASA in the evening when compared with that at Visit 1

    PMID 32959110 · one of two readings recorded this

  • all adverse events of any kind, aspirin fast-release tablets versus placebo

    decreases

    Not recorded as a finding: node adverse-reaction-incidence-ungraded requires events attributed to the study product; all-cause AEs of any kind are not that, and the formulation is fast-release rather than aspirin generally

    For subjects on aspirin FR, we found that they had a significantly decreased risk of 35% of all AEs compared to those on placebo.

    PMID 37603157 · one of two readings recorded this

  • all adverse events of any kind, aspirin FR versus placebo

    decreases, significantly decreased risk of 35%

    Not recorded as a finding: No fitting node: the only adverse-event nodes are an oral supplement event node and a drug-attributed reaction node; all-cause AEs of a drug trial match neither.

    For subjects on aspirin FR, we found that they had a significantly decreased risk of 35% of all AEs compared to those on placebo.

    PMID 37603157 · one of two readings recorded this

  • all AEs

    decreases

    Aspirin FR vs. placebo | 14.4 (98/681) | 20.4 (70/343) | 0.65 [0.48, 0.90]

    PMID 37603157 · one of two readings recorded this

  • all AEs

    no effect

    Aspirin mono (plain only, w/o FR) vs. placebo | 13.5 (377/2794)/ | 13.6 (242/1773) | 1.11 [0.93, 1.33]

    PMID 37603157 · one of two readings recorded this

  • all AEs

    no effect

    All AEs | Aspirin mono vs. placebo | 14.1 (611/4346) | 14.4 (404/2802) | 1.05 [0.91, 1.20]

    PMID 37603157 · one of two readings recorded this

  • all AEs

    no effect

    Aspirin + PSE vs. placebo | 11.3 (81/716) | 10.2 (37/363) | 1.23 [0.82, 1.86]

    PMID 37603157 · one of two readings recorded this

  • all AEs

    no effect

    Aspirin mono (plain only, w/o FR) vs. aspirin FR | 14.7 (62/421) | 15.4 (68/441) | 0.93 [0.64, 1.36]

    PMID 37603157 · one of two readings recorded this

  • all GI AEs

    no effect

    Aspirin FR vs. placebo | 5.9 (40/681) | 8.7 (30/343) | 0.65 [0.41, 1.03]

    PMID 37603157 · one of two readings recorded this

  • all GI AEs

    no effect

    Aspirin mono (plain only, w/o FR) vs. placebo | 3.9 (108/2794) | 4.1 (73/1773) | 0.97 [0.72, 1.30]

    PMID 37603157 · one of two readings recorded this

  • all GI AEs

    no effect

    All GI AEs | Aspirin mono vs. placebo | 5.5 (238/4346) | 6.1 (171/2802) | 1.00 [0.81, 1.23]

    PMID 37603157 · one of two readings recorded this

  • all GI AEs

    no effect

    Aspirin + PSE vs. placebo | 3.5 (25/716) | 3.9 (14/363) | 1.04 [0.53, 2.05]

    PMID 37603157 · one of two readings recorded this

  • all GI AEs

    no effect

    Aspirin mono (plain only, w/o FR) vs. aspirin FR | 4.8 (20/421) | 5.4 (24/441) | 0.87 [0.47, 1.61]

    PMID 37603157 · one of two readings recorded this

  • drug-related all adverse events, aspirin mono (all galenic formulations, alone or combined with vitamin C, caffeine, calcium) versus placebo

    increases, significantly higher risk of 34% and 43% (aspirin mono; aspirin mono plain only)

    Not recorded as a finding: The aspirin mono arm contains combination products absent from the placebo comparator, so the contrast does not isolate aspirin.

    For drug-related all AEs, subjects on aspirin mono and subjects on aspirin mono (plain only, w/o FR) had a signicantly higher risk of 34% and 43%, respectively, than those on placebo.

    PMID 37603157 · one of two readings recorded this

  • drug-related all AEs

    All AEs | 125 (9.44) | 236 (6.09) | 361 (6.94) | 24 (5.14) | 21 (5.83) | 45 (5.44) | 115 (11.20) | 126 (6.10) | 241 (7.80) | 2 (2.70) | 12 (1.66) | 14 (1.76) | 239 (7.33)

    PMID 37603157 · one of two readings recorded this

  • drug-related all AEs

    All AEs | 0 (0.00) | 32 (3.00) | 32 (3.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 20 (4.40) | 20 (4.40) | 0 (0.00) | 12 (1.97) | 12 (1.97) | 22 (6.13)

    PMID 37603157 · one of two readings recorded this

  • drug-related all AEs

    All AEs | 16 (2.87) | 57 (11.35) | 73 (6.89) | 5 (4.63) | 0 (0.00) | 5 (4.63) | 6 (2.20) | 8 (4.91) | 14 (3.21) | 2 (2.70) | 0 (0.00) | 2 (1.74) | 49 (17.44)

    PMID 37603157 · one of two readings recorded this

  • drug-related all AEs

    All AEs | 96 (35.26) | 1 (0.36) | 97 (17.57) | 5 (3.05) | 12 (7.27) | 17 (5.17) | 96 (35.29) | 0 (0.00) | 96 (20.08) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 75 (13.07)

    PMID 37603157 · one of two readings recorded this

  • drug-related all AEs

    decreases

    Aspirin FR vs. placebob | 1.9 (13/681) | 4.7 (16/343) | 0.39 [0.20, 0.79]

    PMID 37603157 · one of two readings recorded this

  • drug-related all AEs

    increases

    Aspirin mono (plain only, w/o FR) vs. placebo | 8.4 (235/2794) | 7.7 (137/1773) | 1.43 [1.13, 1.80]

    PMID 37603157 · one of two readings recorded this

  • drug-related all AEs

    increases

    All AEs | Aspirin mono vs. placeboa | 7.8 (337/4346) | 7.7 (216/2802) | 1.34 [1.11, 1.62]

    PMID 37603157 · one of two readings recorded this

  • drug-related all AEs

    no effect

    Aspirin + PSE vs. placebo | 5.7 (41/716) | 5.8 (21/363) | 1.12[0.65, 1.94]

    PMID 37603157 · one of two readings recorded this

  • drug-related all AEs

    no effect

    Aspirin mono (plain only, w/o FR) vs. aspirin FRb | 3.0 (12/403) | 3.0(12/406) | 1.01 [0.45, 2.28]

    PMID 37603157 · one of two readings recorded this

  • drug-related all GI AEs

    All GI AEs | 16 (1.21) | 140 (3.61) | 156 (3.00) | 11 (2.36) | 5 (1.39) | 16 (1.93) | 14 (1.36) | 60 (2.91) | 74 (2.39) | 1 (1.35) | 6 (0.83) | 7 (0.88) | 116 (3.56)

    PMID 37603157 · one of two readings recorded this

  • drug-related all GI AEs

    All GI AEs | 0 (0.00) | 14 (1.31) | 14 (1.31) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 8 (1.76) | 8 (1.76) | 0 (0.00) | 6 (0.98) | 6 (0.98) | 7 (1.95)

    PMID 37603157 · one of two readings recorded this

  • drug-related all GI AEs

    All GI AEs | 5 (0.90) | 50 (9.96) | 55 (5.19) | 2 (1.85) | 0 (0.00) | 2 (1.85) | 3 (1.10) | 6 (3.68) | 9 (2.06) | 1 (1.35) | 0 (0.00) | 1 (0.87) | 45 (16.01)

    PMID 37603157 · one of two readings recorded this

  • drug-related all GI AEs

    All GI AEs | 3 (1.10) | 1 (0.36) | 4 (0.72) | 2 (1.22) | 4 (2.42) | 6 (0.74) | 3 (1.10) | 0 (0.00) | 3 (0.63) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 13 (2.26)

    PMID 37603157 · one of two readings recorded this

  • drug-related all GI AEs

    no effect

    Aspirin FR vs. placebob | 1.0 (7/681) | 2.3 (8/343) | 0.43 [0.17, 1.13]

    PMID 37603157 · one of two readings recorded this

  • drug-related all GI AEs

    no effect

    Aspirin mono (plain only, w/o FR) vs. placebo | 2.6 (72/2794) | 2.4 (43/1773) | 1.14 [0.78, 1.67]

    PMID 37603157 · one of two readings recorded this

  • drug-related all GI AEs

    no effect

    All GI AEs | Aspirin mono vs. placeboa | 3.5 (150/4346) | 3.9 (109/2802) | 1.14 [0.88, 1.48]

    PMID 37603157 · one of two readings recorded this

  • drug-related all GI AEs

    no effect

    Aspirin + PSE vs. placebo | 2.1 (15/716) | 3.0 (11/363) | 0.83 [0.37, 1.87]

    PMID 37603157 · one of two readings recorded this

  • drug-related all GI AEs

    no effect

    Aspirin mono (plain only, w/o FR) vs. aspirin FRb | 2.0 (8/403) | 1.5 (6/406) | 1.35 [0.46, 3.92]

    PMID 37603157 · one of two readings recorded this

  • drug-related dyspepsia

    Dyspepsia | 5 (0.38) | 52 (1.34) | 57 (1.10) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 5 (0.49) | 16 (0.78) | 21 (0.68) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 44 (1.35)

    PMID 37603157 · one of two readings recorded this

  • drug-related dyspepsia

    Dyspepsia | 0 (0.00) | 28 (5.58) | 28 (2.64) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 29 (10.32)

    PMID 37603157 · one of two readings recorded this

  • drug-related dyspepsia

    Dyspepsia | 3 (1.10) | 1 (0.36) | 4 (0.72) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 3 (1.10) | 0 (0.00) | 3 (0.63) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 4 (0.70)

    PMID 37603157 · one of two readings recorded this

  • drug-related dyspepsia

    no effect

    Aspirin FR vs. placebob | 0.1 (1/681) | 0.3 (1/343) | 0.50 [0.04, 6.75]c

    PMID 37603157 · one of two readings recorded this

  • drug-related dyspepsia

    no effect

    Aspirin mono (plain only, w/o FR) vs. placebo | 0.8 (22/2794) | 0.5 (8/1773) | 1.98 [0.88, 4.46]

    PMID 37603157 · one of two readings recorded this

  • drug-related dyspepsia

    no effect

    Dyspepsia | Aspirin mono vs. placeboa | 1.3 (58/4346) | 1.6 (45/2802) | 1.24 [0.82, 1.88]

    PMID 37603157 · one of two readings recorded this

  • drug-related dyspepsia

    no effect

    Aspirin + PSE vs. placebo | 0.1 (1/716) | 0.8 (3/363) | 0.32 [0.02, 4.91]

    PMID 37603157 · one of two readings recorded this

  • drug-related dyspepsia

    no effect

    Aspirin mono (plain only, w/o FR) vs. aspirin FRb | 0.2 (1/403) | 0.2 (1/406) | 1.01 [0.06, 16.20]c

    PMID 37603157 · one of two readings recorded this

  • drug-related GI bleeding

    no effect

    GI bleeding | Aspirin mono vs. placeboa | 0.0 (1/4346) | 0.1 (3/2802) | 0.23 [0.03, 1.70]

    PMID 37603157 · one of two readings recorded this

  • drug-related minor GI AEs

    Minor GI AEs | 6 (0.45) | 58 (1.50) | 64 (1.23) | 2 (0.43) | 3 (0.83) | 5 (0.60) | 6 (0.58) | 32 (1.55) | 38 (1.23) | 0 (0.00) | 6 (0.83) | 6 (0.75) | 49 (1.50)

    PMID 37603157 · one of two readings recorded this

  • drug-related minor GI AEs

    Minor GI AEs | 0 (0.00) | 14 (1.31) | 14 (1.31) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 8 (1.76) | 8 (1.76) | 0 (0.00) | 6 (0.98) | 6 (0.98) | 7 (1.95)

    PMID 37603157 · one of two readings recorded this

  • drug-related minor GI AEs

    Minor GI AEs | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 3 (1.82) | 3 (0.91) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 5 (0.87)

    PMID 37603157 · one of two readings recorded this

  • drug-related minor GI AEs

    no effect

    Aspirin FR vs. placebob | 1.0 (7/681) | 2.3 (8/343) | 0.43 [0.17, 1.13]

    PMID 37603157 · one of two readings recorded this

  • drug-related minor GI AEs

    no effect

    Aspirin mono (plain only, w/o FR) vs. placebo | 1.4 (38/2794) | 1.5 (26/1773) | 0.93 [0.57, 1.51]

    PMID 37603157 · one of two readings recorded this

  • drug-related minor GI AEs

    no effect

    Minor GI AEs | Aspirin mono vs. placeboa | 1.4 (62/4346) | 1.6 (45/2802) | 0.93 [0.63, 1.38]

    PMID 37603157 · one of two readings recorded this

  • drug-related minor GI AEs

    no effect

    Aspirin + PSE vs. placebo | 0.7 (5/716) | 1.7 (6/363) | 0.47 [0.14, 1.56]

    PMID 37603157 · one of two readings recorded this

  • drug-related minor GI AEs

    no effect

    Aspirin mono (plain only, w/o FR) vs. aspirin FRb | 2.0 (8/403) | 1.5 (6/406) | 1.35 [0.46, 3.92]

    PMID 37603157 · one of two readings recorded this

  • drug-unrelated all AEs

    All AEs | 56 (4.23) | 285 (7.35) | 341 (6.56) | 33 (7.07) | 20 (5.56) | 53 (6.41) | 38 (3.70) | 129 (6.25) | 167 (5.40) | 9 (12.16) | 89 (12.33) | 98 (12.31) | 227 (6.97)

    PMID 37603157 · one of two readings recorded this

  • drug-unrelated all AEs

    All AEs | 0 (0.00) | 129 (12.11) | 129 (12.11) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 54 (11.87) | 54 (11.87) | 0 (0.00) | 75 (12.30) | 75 (12.30) | 52 (14.48)

    PMID 37603157 · one of two readings recorded this

  • drug-unrelated all AEs

    All AEs | 28 (5.03) | 59 (11.75) | 87 (8.22) | 12 (11.11) | 0 (0.00) | 12 (11.11) | 10 (3.66) | 32 (19.63) | 42 (9.63) | 9 (12.16) | 1 (2.44) | 10 (8.70) | 47 (16.73)

    PMID 37603157 · one of two readings recorded this

  • drug-unrelated all AEs

    All AEs | 3 (1.10) | 14 (5.00) | 17 (3.08) | 3 (1.83) | 5 (3.03) | 8 (2.43) | 3 (1.10) | 1 (0.49) | 4 (0.84) | 0 (0.00) | 13 (18.31) | 13 (18.31) | 21 (3.66)

    PMID 37603157 · one of two readings recorded this

  • drug-unrelated all GI AEs

    All GI AEs | 8 (0.60) | 96 (2.48) | 104 (2.00) | 6 (1.28) | 5 (1.39) | 11 (1.33) | 6 (0.58) | 36 (1.74) | 42 (1.36) | 2 (2.70) | 34 (4.71) | 36 (4.52) | 67 (2.06)

    PMID 37603157 · one of two readings recorded this

  • drug-unrelated all GI AEs

    All GI AEs | 0 (0.00) | 43 (4.04) | 43 (4.04) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 12 (2.64) | 12 (2.64) | 0 (0.00) | 31 (5.08) | 31 (5.08) | 25 (6.96)

    PMID 37603157 · one of two readings recorded this

  • drug-unrelated all GI AEs

    All GI AEs | 3 (0.54) | 21 (4.18) | 24 (2.27) | 1 (0.93) | 0 (0.00) | 1 (0.93) | 1 (0.37) | 9 (5.52) | 10 (2.29) | 2 (2.70) | 0 (0.00) | 2 (1.74) | 10 (3.56)

    PMID 37603157 · one of two readings recorded this

  • drug-unrelated all GI AEs

    All GI AEs | 0 (0.00) | 4 (1.43) | 4 (0.72) | 2 (1.22) | 2 (1.21) | 4 (1.22) | 0 (0.00) | 1 (0.49) | 1 (0.21) | 0 (0.00) | 3 (4.23) | 3 (4.23) | 5 (0.87)

    PMID 37603157 · one of two readings recorded this

  • drug-unrelated dyspepsia

    Dyspepsia | 0 (0.00) | 11 (0.28) | 11 (0.21) | 1 (0.21) | 0 (0.00) | 1 (0.12) | 0 (0.00) | 1 (0.05) | 1 (0.03) | 0 (0.00) | 1 (0.14) | 1 (0.13) | 4 (0.12)

    PMID 37603157 · one of two readings recorded this

  • drug-unrelated dyspepsia

    Dyspepsia | 0 (0.00) | 1 (0.09) | 1 (0.09) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 1 (0.16) | 1 (0.16) | 1 (0.28)

    PMID 37603157 · one of two readings recorded this

  • drug-unrelated dyspepsia

    Dyspepsia | 0 (0.00) | 8 (1.59) | 8 (0.76) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 3 (1.07)

    PMID 37603157 · one of two readings recorded this

  • drug-unrelated minor GI AEs

    Minor GI AEs | 3 (0.23) | 58 (1.50) | 61 (1.17) | 2 (0.43) | 3 (0.83) | 5 (0.60) | 2 (0.19) | 22 (1.07) | 24 (0.78) | 1 (1.35) | 26 (3.60) | 27 (3.39) | 46 (1.41)

    PMID 37603157 · one of two readings recorded this

  • drug-unrelated minor GI AEs

    Minor GI AEs | 0 (0.00) | 32 (3.00) | 32 (3.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 8 (1.76) | 8 (1.76) | 0 (0.00) | 24 (3.93) | 24 (3.93) | 20 (5.57)

    PMID 37603157 · one of two readings recorded this

  • drug-unrelated minor GI AEs

    Minor GI AEs | 1 (0.18) | 11 (2.19) | 12 (1.13) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 9 (5.52) | 9 (2.06) | 1 (1.35) | 0 (0.00) | 1 (0.87) | 8 (2.85)

    PMID 37603157 · one of two readings recorded this

  • drug-unrelated minor GI AEs

    Minor GI AEs | 0 (0.00) | 2 (0.71) | 2 (0.36) | 0 (0.00) | 1 (0.61) | 1 (0.30) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 2 (2.82) | 2 (2.82) | 1 (0.17)

    PMID 37603157 · one of two readings recorded this

  • dyspepsia

    no effect

    Aspirin FR vs. placebo | 0.3 (2/681) | 0.6 (2/343) | 0.50 [0.08, 3.02]

    PMID 37603157 · one of two readings recorded this

  • dyspepsia

    no effect

    aspirin mono (plain only, w/o FR) vs. placebo | 0.8 (22/2794) | 0.5 (9/1773) | 1.72 [0.80, 3.71]

    PMID 37603157 · one of two readings recorded this

  • dyspepsia

    no effect

    Dyspepsia | Aspirin mono vs. placebo | 1.5 (64/4346) | 1.7 (49/2802) | 1.24 [0.83, 1.85]

    PMID 37603157 · one of two readings recorded this

  • dyspepsia

    no effect

    Aspirin + PSE vs. placebo | 0.3 (2/716) | 0.8 (3/363) | 0.61 [0.07, 5.37]

    PMID 37603157 · one of two readings recorded this

  • dyspepsia

    no effect

    Aspirin mono (plain only, w/o FR) vs. aspirin FR | 0.2 (1/421) | 0.5 (2/441) | 0.54 [0.05, 5.76]

    PMID 37603157 · one of two readings recorded this

  • GI bleeding

    no effect

    Aspirin FR vs. placebo | 0.1 (1/681) | 0.3 (1/343) | 0.50 [0.04, 6.75]

    PMID 37603157 · one of two readings recorded this

  • GI bleeding

    no effect

    Aspirin mono (plain only, w/o FR) vs. placebo | 0.0 (1/2794) | 0.1 (2/1773) | 0.30 [0.04, 2.39]

    PMID 37603157 · one of two readings recorded this

  • GI bleeding

    no effect

    GI bleeding | Aspirin mono vs. placebo | 0.0 (1/4346) | 0.1 (3/2802) | 0.23 [0.03, 1.70]

    PMID 37603157 · one of two readings recorded this

  • GI bleeding

    no effect

    Aspirin + PSE vs. placebo | 0.1 (1/716) | 0.6 (2/363) | 0.26 [0.03, 2.23]

    PMID 37603157 · one of two readings recorded this

  • GI bleeding

    no effect

    Aspirin mono (plain only, w/o FR) vs. aspirin FR | 0.2 (1/421) | 0.2 (1/441) | 1.05 [0.06, 17.08]

    PMID 37603157 · one of two readings recorded this

  • minor GI AEs

    no effect

    Aspirin FR vs. placebo | 4.7 (32/681/) | 6.7 (23/343) | 0.68 [0.41, 1.15]

    PMID 37603157 · one of two readings recorded this

  • minor GI AEs

    no effect

    Aspirin mono (plain only, w/o FR) vs. placebo | 2.1 (59/2794) | 2.7 (48/1773) | 0.77 [0.53, 1.13]

    PMID 37603157 · one of two readings recorded this

  • minor GI AEs

    no effect

    Minor GI AEs | Aspirin mono vs. placebo | 2.7 (118/4346) | 3.2 (89/2802) | 0.81 [0.61, 1.07]

    PMID 37603157 · one of two readings recorded this

  • minor GI AEs

    no effect

    aspirin + PSE vs. placebo | 1.4 (10/716) | 1.9 (7/363) | 0.79 [0.30, 2.11]

    PMID 37603157 · one of two readings recorded this

  • minor GI AEs

    no effect

    Aspirin mono (plain only, w/o FR) vs. aspirin FR | 3.8 (16/421) | 4.5 (20/441) | 0.83 [0.42, 1.63]

    PMID 37603157 · one of two readings recorded this

  • subjects with at least 1 AE

    Number of subjects with at least 1 AE | 179 (13.52) | 490 (12.64) | 669 (12.86) | 55 (11.78) | 41 (11.39) | 96 (11.61) | 151 (14.70) | 241 (11.68) | 392 (12.68) | 11 (14.86) | 99 (13.71) | 110 (13.82) | 443 (13.59)

    PMID 37603157 · one of two readings recorded this

  • subjects with at least 1 AE

    Number of subjects with at least 1 AE | 0 (0.00) | 156 (14.65) | 156 (14.65) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 71 (15.60) | 71 (15.60) | 0 (0.00) | 85 (13.93) | 85 (13.93) | 70 (19.50)

    PMID 37603157 · one of two readings recorded this

  • subjects with at least 1 AE

    Number of subjects with at least 1 AE | 44 (7.90) | 105 (20.92) | 149 (14.07) | 16 (14.81) | 0 (0.00) | 16 (14.81) | 16 (5.89) | 36 (22.09) | 52 (11.93) | 11 (14.86) | 1 (2.44) | 12 (10.43) | 90 (32.03)

    PMID 37603157 · one of two readings recorded this

  • subjects with at least 1 AE

    Number of subjects with at least 1 AE | 99 (36.40) | 15 (5.36) | 114 (20.65) | 8 (4.88) | 17 (10.30) | 25 (7.60) | 99 (36.40) | 1 (0.49) | 100 (20.91) | 0 (0.00) | 13 (18.31) | 13 (18.31) | 96 (16.72)

    PMID 37603157 · one of two readings recorded this

  • ADC kurtosis

    no effect

    ADC Kurtosis (-) mean ± SD | 3.38 ± 1.54 | 3.03 ± 0.99 | 3.01 ± 0.99 | 3.00 ± 0.61

    PMID 38317255 · one of two readings recorded this

  • ADC kurtosis

    no effect

    ADC Kurtosis (-) mean ± SD | 3.38 ± 1.54 | 3.03 ± 0.99 | 3.01 ± 0.99 | 3.00 ± 0.61

    PMID 38317255 · one of two readings recorded this

  • ADC

    no effect

    ADC (10–3 mm2 / s) mean ± SD | 1.39 ± 0.41 | 1.28 ± 0.43 | 1.40 ± 0.37 | 1.38 ± 0.39

    PMID 38317255 · one of two readings recorded this

  • ADC

    no effect

    ADC (10–3 mm2 / s) mean ± SD | 1.39 ± 0.41 | 1.28 ± 0.43 | 1.40 ± 0.37 | 1.38 ± 0.39

    PMID 38317255 · one of two readings recorded this

  • additional inflammatory proteins changed in breast tissue before FDR correction

    modulates, p = 0.05, n = 25

    An additional 17 proteins in breast tissue showed changes after 6 months of ASA with a p < 0.05 although not after FDR correction

    PMID 38317255 · one of two readings recorded this

  • correlation of wash-out rate with VEGF

    increases, p = 0.01

    The wash-out rate correlated significantly with the potent angiogenic factor VEGF (p < 0.01, Spearman’s r = 0.359)

    PMID 38317255 · one of two readings recorded this

  • IL-7 and IL-13 in abdominal subcutaneous fat before FDR correction

    decreases, p = 0.05, n = 25

    Levels of IL-7 and IL-13 were lower in abdominal s.c. fat with a p < 0.05 but not after FDR correction

    PMID 38317255 · one of two readings recorded this

  • in vivo breast tissue levels of 92 inflammatory proteins by microdialysis and proximity extension assay, plus breast MRI perfusion wash-in and wash-out and lean tissue fraction, ASA 160 mg/day versus no treatment for 6 months

    decreases, 20 of 92 inflammatory proteins decreased in breast tissue after 6 months of ASA

    Not recorded as a finding: this platform holds no node for the endpoint

    Out of these 92 proteins, 20 showed decreases in breast tissue after 6 months of ASA therapy.

    PMID 38317255 · one of two readings recorded this

  • inflammatory proteins altered in abdominal subcutaneous fat

    no effect, n = 25

    none of the proteins that were affected in breast tissue were altered in abdominal s.c. fat

    PMID 38317255 · one of two readings recorded this

  • inflammatory proteins decreased in breast tissue after FDR correction

    decreases, n = 25

    Out of these 92 proteins, 20 showed decreases in breast tissue after 6 months of ASA therapy

    PMID 38317255 · one of two readings recorded this

  • inflammatory proteins in breast tissue and abdominal subcutaneous fat

    no effect, n = 24

    In the no-treatment group, no changes in protein levels were observed in breast tissue or abdominal s.c. fat after 6 months

    PMID 38317255 · one of two readings recorded this

  • lean tissue fraction (LTF)

    no effect

    No differences were found in either group, either with or without Gd3+-containing contrast agent

    PMID 38317255 · one of two readings recorded this

  • local breast tissue inflammatory protein levels in microdialysate, 92-protein Olink proximity extension assay, aspirin 160 mg/day versus no treatment for 6 months; also breast perfusion and lean tissue fraction by MRI

    decreases, 20 of 92 proteins decreased in breast tissue after FDR correction

    Not recorded as a finding: this platform holds no node for the endpoint

    Out of these 92 proteins, 20 showed decreases in breast tissue after 6 months of ASA therapy.

    PMID 38317255 · one of two readings recorded this

  • MCP-3 and IL-20 in breast tissue before FDR correction

    decreases, n = 24

    In the no-treatment group after 6 months, MCP-3 and IL-20 levels were lower in breast tissue

    PMID 38317255 · one of two readings recorded this

  • PD proton density, fibroglandular tissue

    no effect

    PD (%; fibroglandular, whole breast) | 84 ± 4 | 84 ± 3.9 | 85 ± 3.4 | 85 ± 3.5

    PMID 38317255 · one of two readings recorded this

  • PD proton density, fibroglandular tissue

    no effect

    PD (%; fibroglandular, whole breast) | 84 ± 4 | 84 ± 3.9 | 85 ± 3.4 | 85 ± 3.5

    PMID 38317255 · one of two readings recorded this

The whole record — 323 rows